Current approaches targeting androgens/AR in PCa include treatment with gonadotropin receptor agonists and antagonists [16], inhibition of 5α-reductase [17], [18], inhibition of the steroidogenic enzyme CYP17A1 [19], blockade of AR ligand binding (e.g. MDV3100) [20]–[22] and the AR N-terminal domain binding (e.g. EPI-001) [23]. The gene discussed is CYP17A1; the disease is posterior cortical atrophy.